480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1819099913598795776 |
|---|---|
| author | Susanna Ulahannan Manish Patel Gerald Falchook David Spigel Babar Bashir Christine Duffy Daniela Maier Hisaya Azuma |
| author_facet | Susanna Ulahannan Manish Patel Gerald Falchook David Spigel Babar Bashir Christine Duffy Daniela Maier Hisaya Azuma |
| author_sort | Susanna Ulahannan |
| collection | DOAJ |
| first_indexed | 2024-12-22T00:54:26Z |
| format | Article |
| id | doaj.art-672be4c7aea64636b93f84c470fcaf08 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-22T00:54:26Z |
| publishDate | 2021-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-672be4c7aea64636b93f84c470fcaf082022-12-21T18:44:22ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-11-019Suppl 210.1136/jitc-2021-SITC2021.480480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6Susanna Ulahannan0Manish Patel1Gerald Falchook2David Spigel3Babar Bashir4Christine Duffy5Daniela Maier6Hisaya Azuma74University of Oklahoma Health Sciences C, OKC, OK, USAGeneral Medicine, University Hospital Wishaw, Wishaw, UKAff111 SCRI at HealthONE Denver CO USASarah Cannon Research Institute, Nashville, Tennessee, USA4Thomas Jefferson University, Philadelphia, PA, USA6Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA7Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss, Germany8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany |
| spellingShingle | Susanna Ulahannan Manish Patel Gerald Falchook David Spigel Babar Bashir Christine Duffy Daniela Maier Hisaya Azuma 480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6 Journal for ImmunoTherapy of Cancer |
| title | 480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6 |
| title_full | 480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6 |
| title_fullStr | 480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6 |
| title_full_unstemmed | 480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6 |
| title_short | 480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6 |
| title_sort | 480 a first in human phase i dose escalation trial of the b7 h6 cd3 t cell engager bi 765049 ezabenlimab bi 754091 in patients with advanced solid tumors expressing b7 h6 |
| work_keys_str_mv | AT susannaulahannan 480afirstinhumanphaseidoseescalationtrialoftheb7h6cd3tcellengagerbi765049ezabenlimabbi754091inpatientswithadvancedsolidtumorsexpressingb7h6 AT manishpatel 480afirstinhumanphaseidoseescalationtrialoftheb7h6cd3tcellengagerbi765049ezabenlimabbi754091inpatientswithadvancedsolidtumorsexpressingb7h6 AT geraldfalchook 480afirstinhumanphaseidoseescalationtrialoftheb7h6cd3tcellengagerbi765049ezabenlimabbi754091inpatientswithadvancedsolidtumorsexpressingb7h6 AT davidspigel 480afirstinhumanphaseidoseescalationtrialoftheb7h6cd3tcellengagerbi765049ezabenlimabbi754091inpatientswithadvancedsolidtumorsexpressingb7h6 AT babarbashir 480afirstinhumanphaseidoseescalationtrialoftheb7h6cd3tcellengagerbi765049ezabenlimabbi754091inpatientswithadvancedsolidtumorsexpressingb7h6 AT christineduffy 480afirstinhumanphaseidoseescalationtrialoftheb7h6cd3tcellengagerbi765049ezabenlimabbi754091inpatientswithadvancedsolidtumorsexpressingb7h6 AT danielamaier 480afirstinhumanphaseidoseescalationtrialoftheb7h6cd3tcellengagerbi765049ezabenlimabbi754091inpatientswithadvancedsolidtumorsexpressingb7h6 AT hisayaazuma 480afirstinhumanphaseidoseescalationtrialoftheb7h6cd3tcellengagerbi765049ezabenlimabbi754091inpatientswithadvancedsolidtumorsexpressingb7h6 |